nilutamide has been researched along with Bone Cancer in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nilutamide and placebo were evaluated for efficacy in 207 and 216 patients, respectively." | 2.67 | Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. ( Abbou, CC; Bartoletti, R; Bernstein-Hahn, L; Bracken, B; Brisset, JM; Chisholm, G; Crawford, ED; Da Silva, FC; Debruyne, FM; Janknegt, RA, 1993) |
| "Two cases of metastatic prostate cancer demonstrating decrease in PSA of 92% and 56% on discontinuation of nilutamide therapy are reported." | 1.30 | Antiandrogen withdrawal syndrome with nilutamide. ( Gerridzen, RG; Huan, SD; Stewart, DJ; Yau, JC, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 7 (77.78) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sartor, AO | 1 |
| Tangen, CM | 1 |
| Hussain, MH | 1 |
| Eisenberger, MA | 1 |
| Parab, M | 1 |
| Fontana, JA | 1 |
| Chapman, RA | 1 |
| Mills, GM | 1 |
| Raghavan, D | 1 |
| Crawford, ED | 2 |
| Labrie, F | 1 |
| Dupont, A | 1 |
| Belanger, A | 1 |
| Cusan, L | 1 |
| Lacourciere, Y | 1 |
| Monfette, G | 1 |
| Laberge, JG | 1 |
| Emond, JP | 1 |
| Fazekas, AT | 1 |
| Raynaud, JP | 1 |
| Husson, JM | 1 |
| Janknegt, RA | 2 |
| Abbou, CC | 2 |
| Bartoletti, R | 1 |
| Bernstein-Hahn, L | 1 |
| Bracken, B | 1 |
| Brisset, JM | 1 |
| Da Silva, FC | 1 |
| Chisholm, G | 1 |
| Debruyne, FM | 1 |
| Bertagna, C | 1 |
| De Géry, A | 1 |
| Hucher, M | 1 |
| François, JP | 1 |
| Zanirato, J | 1 |
| Huan, SD | 1 |
| Gerridzen, RG | 1 |
| Yau, JC | 1 |
| Stewart, DJ | 1 |
| Smith, JA | 1 |
| Lange, PH | 1 |
| deGery, A | 1 |
| Shimazaki, J | 1 |
| Higa, T | 1 |
| Akimoto, S | 1 |
| Masai, M | 1 |
| Isaka, S | 1 |
| Decensi, A | 1 |
| Guarneri, D | 1 |
| Paoletti, MC | 1 |
| Lalanne, JM | 1 |
| Merlo, F | 1 |
| Boccardo, F | 1 |
| Béland, G | 1 |
| Elhilali, M | 1 |
| Fradet, Y | 1 |
| Laroche, B | 1 |
| Ramsey, EW | 1 |
| Trachtenberg, J | 1 |
| Venner, PM | 1 |
| Tewari, HD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer[NCT01875250] | Phase 2 | 38 participants (Actual) | Interventional | 2013-07-22 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Normal testosterone is 270-1070 nd/dL. (NCT01875250)
Timeframe: 84 days
| Intervention | ng/dl (Median) |
|---|---|
| All Participants | 834 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01875250)
Timeframe: Date treatment consent signed to date off study, approximately 43 months and 13 days for Arm A, and 78 months and 6 days for Arm B.
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A - Enzalutamide for 3 Months | 19 |
| Arm B - Enzalutamide for 3 Months + PSA-TRICOM | 19 |
Median PSA change would be considered optimal. (NCT01875250)
Timeframe: 84 days
| Intervention | Percent change (Median) |
|---|---|
| Arm A - Enzalutamide for 3 Months | -99 |
| Arm B - Enzalutamide for 3 Months + PSA-TRICOM | -99 |
Growth rate was measured using the growth rate equation -f(t) = exp (-d*t) + exp (g*t) -1 where exp is the base of the natural algorithm, e = 2.7182 and t is days since treatment started. The tumor growth rate equation measures Prostate Specific Antigen (PSA) rise over time. The UOM is unitless because this is a way to measure PSA kinetics. (NCT01875250)
Timeframe: 7 months
| Intervention | unitless (Number) |
|---|---|
| Arm A - Enzalutamide for 3 Months | 0.031 |
| Arm B - Enzalutamide for 3 Months + PSA-TRICOM | 0.030 |
VEGF was measured by the enzyme-linked immunosorbent assay (ELISA) assay. The lower limit of quantitation of assay was 9.0 pg/ml. (NCT01875250)
Timeframe: 30 Days After the Start of Course 1 and Course 2 of Enzalutamide
| Intervention | pg/ml (Mean) | |
|---|---|---|
| Course 1 | Course 2 | |
| All Participants | 192 | 165.04 |
PSA recovery is defined as the return above baseline PSA in participants with normal testosterone and non-metastatic, castration sensitive prostate cancer. (NCT01875250)
Timeframe: up to 41 months
| Intervention | Days (Median) | |
|---|---|---|
| Course 1 | Course 2 | |
| All Participants | 224 | 189 |
1 review available for nilutamide and Bone Cancer
| Article | Year |
|---|---|
Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).
Topics: Acid Phosphatase; Alkaline Phosphatase; Androgen Antagonists; Antineoplastic Agents; Biomarkers, Tum | 1994 |
5 trials available for nilutamide and Bone Cancer
| Article | Year |
|---|---|
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Bone Neoplasms; Disease-Fre | 2008 |
Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.
Topics: Acid Phosphatase; Actuarial Analysis; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms | 1993 |
Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
Topics: Acid Phosphatase; Alkaline Phosphatase; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone | 1997 |
Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer. Italian Prostatic Cancer Project (PONCAP).
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Drug Evaluation; Estradiol; Humans; Imidazoles; Imidazo | 1991 |
A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Bone Neoplasms; Combined Modality Therapy; Dou | 1990 |
3 other studies available for nilutamide and Bone Cancer
| Article | Year |
|---|---|
New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
Topics: Adenocarcinoma; Androgen Antagonists; Animals; Bone Neoplasms; Buserelin; Drug Therapy, Combination; | 1982 |
Antiandrogen withdrawal syndrome with nilutamide.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Neoplasms; Humans; Imidazoles; Imidazolidines; M | 1997 |
Clinical course of bone metastasis from prostatic cancer following endocrine therapy: examination with bone x-ray.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Chlormadinone Acetate; Combined Modality Therapy; Estrogens | 1992 |